Antinuclear antibodies (ANA) are autoantibodies that target components within the cell nucleus, such as DNA, RNA, and nuclear proteins. Their presence reflects dysregulation of immune tolerance and is commonly associated with systemic autoimmune diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome, and scleroderma. ANA levels can fluctuate with disease activity, making them a useful biomarker for detecting autoimmune processes and understanding the underlying immune response. Quantitative measurement of ANA provides more detailed information than traditional qualitative assays, allowing for assessment of antibody concentration and potential correlation with disease severity.
The ANA Screen Quantitative ELISA enables sensitive and specific detection of a broad spectrum of antinuclear antibodies in serum or plasma. In research settings, this assay is used to study autoimmune pathogenesis, evaluate immune dysregulation in experimental models, and identify novel autoantibody profiles associated with disease onset or progression. It can also be employed to monitor the effects of therapeutic interventions on autoantibody production and immune system modulation.
Clinically, ANA quantitative ELISA is an important tool for the diagnosis and monitoring of autoimmune disorders. It helps confirm suspected autoimmune disease, stratify patients based on antibody levels, and guide treatment decisions. In some cases, serial measurements can provide insight into disease activity or response to immunosuppressive therapy, supporting more personalized management of patients with systemic autoimmune conditions.
This product is manufactured in Germany by Medipan GmbH.
| Size | 1 x 96 Well |
| Sensitivity | 8 U/mL |
| Incubation Time | 1 hour 45 minutes |
| Sample Type | Serum |
| Storage | 2-8°C |
| Alternative Names | Antinuclear Antibody Test, Antinuclear Antibody Assay, ANA Panel, and ANA Titer. |
